Natalie Doyle
Internal Medicine · Jacksonville, FLNPI 1932104940
Payments from drug & device makers
Across 65 payments — averaging $19.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$305
- Amgen$143
- Pfizer$129
- Genentech USA, Inc.$104
- Lilly USA, LLC$74
- Kowa Pharmaceuticals America, Inc.$60
- plus $424 from 14 others
What the payments were for
- Food & beverage$1,239100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 20 | $305 |
| Amgen | 5 | $143 |
| Pfizer | 7 | $129 |
| Genentech USA, Inc. | 1 | $104 |
| Lilly USA, LLC | 4 | $74 |
| Kowa Pharmaceuticals America, Inc. | 4 | $60 |
| Melinta Therapeutics, LLC | 3 | $58 |
| Merck | 3 | $51 |
| AstraZeneca | 4 | $51 |
| Sunovion Pharmaceuticals Inc. | 1 | $45 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Lundbeck LLC | 1 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| AbbVie | 2 | $27 |
| Dexcom, Inc. | 1 | $25 |
| Eisai Inc. | 1 | $20 |
| Novartis | 1 | $18 |
| Medtronic | 1 | $18 |
| Boehringer Ingelheim | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $13 |
How this compares
$1,239 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 109 | $99,897 |
| XeljanzTofacitinib Citrate | 13 | $70,377 |
| OzempicSemaglutide | 43 | $53,307 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $43,795 |
| TrulicityDulaglutide | 22 | $23,037 |
| XareltoRivaroxaban | 18 | $18,333 |
| FarxigaDapagliflozin Propanediol | 14 | $16,773 |
| MyrbetriqMirabegron | 19 | $16,659 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $11,231 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 71 | $10,876 |
| LinzessLinaclotide | 16 | $10,417 |
| Spiriva RespimatTiotropium Bromide | 11 | $6,701 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $6,254 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $6,107 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 193 | $5,782 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Xeljanz | $129 | $170,274122 claims |
| Novo NordiskOzempic | $305 | $53,30743 claims |
| Lilly USA, LLCTrulicity | $74 | $23,03722 claims |
| AstraZenecaFarxiga | $51 | $16,77314 claims |
| AbbVieLinzess | $27 | $10,41716 claims |
| Boehringer IngelheimSpiriva Respimat | $14 | $6,70111 claims |
| Sanofi-aventis U.S. LLCLantus | $31 | $1,19611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Jacksonville
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.